Citadel Advisors
FULC icon

Citadel Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Citadel Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.9M Buy
2,704,505
+1,412,019
+109% +$8.59M ﹤0.01% 3592
2026
Q1 		$9.91M Buy
1,292,486
+85,482
+7% +$793K ﹤0.01% 3271
2025
Q4 		$13.7M Buy
1,207,004
+352,448
+41% +$3.59M ﹤0.01% 2829
2025
Q3 		$7.86M Buy
854,556
+688,322
+414% +$4.98M ﹤0.01% 3604
2025
Q2 		$1.14M Sell
166,234
-208,022
-56% -$1.11M ﹤0.01% 6784
2025
Q1 		$1.08M Buy
374,256
+40,933
+12% +$150K ﹤0.01% 6796
2024
Q4 		$1.57M Sell
333,323
-1,015,470
-75% -$3.75M ﹤0.01% 6132
2024
Q3 		$4.82M Sell
1,348,793
-428,319
-24% -$3.18M ﹤0.01% 4002
2024
Q2 		$11M Buy
1,777,112
+451,733
+34% +$3.42M ﹤0.01% 2656
2024
Q1 		$12.5M Sell
1,325,379
-78,494
-6% -$701K ﹤0.01% 2635
2023
Q4 		$9.48M Buy
1,403,873
+149,689
+12% +$664K ﹤0.01% 2921
2023
Q3 		$5.57M Sell
1,254,184
-250,455
-17% -$1.09M ﹤0.01% 3493
2023
Q2 		$4.97M Buy
1,504,639
+1,295,180
+618% +$3.81M ﹤0.01% 3667
2023
Q1 		$597K Sell
209,459
-606,785
-74% -$5.44M ﹤0.01% 7952
2022
Q4 		$5.94M Buy
816,244
+174,112
+27% +$1.14M ﹤0.01% 3581
2022
Q3 		$5.2M Buy
642,132
+586,085
+1,046% +$4.2M ﹤0.01% 3798
2022
Q2 		$275K Sell
56,047
-56,156
-50% -$549K ﹤0.01% 9984
2022
Q1 		$2.65M Sell
112,203
-58,758
-34% -$832K ﹤0.01% 5453
2021
Q4 		$3.02M Sell
170,961
-142,949
-46% -$2.83M ﹤0.01% 5318
2021
Q3 		$8.86M Sell
313,910
-96,615
-24% -$1.83M ﹤0.01% 3277
2021
Q2 		$4.3M Buy
+410,525
New +$4.15M ﹤0.01% 4767

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors's FULC Position: Q2 2026 in Review

Citadel Advisors increased its Fulcrum Therapeutics (FULC) stake by 109% in Q2 2026, buying an estimated $8.59M and bringing the position to 2,704,505 shares worth $9.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3592.

Citadel Advisors first reported a position in FULC in Q2 2021 and has held it in 21 quarters since. The position peaked at $13.7M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Citadel Advisors held 2,704,505 shares of Fulcrum Therapeutics worth $9.9M as of Q2 2026.
  • Citadel Advisors bought 1,412,019 Fulcrum Therapeutics shares in Q2 2026, an estimated $8.59M.
  • Fulcrum Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3592 holding.
  • Citadel Advisors first reported a position in Fulcrum Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Fulcrum Therapeutics position peaked at $13.7M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.